Monday - February 16, 2026

Category Archives: Pharmaceuticals & Biotech

Ovarian Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Ovarian Cancer pipeline constitutes 180+ key companies continuously working towards developing 200+ Ovarian Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Neuroendocrine Tumors Pipeline 2025: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | Novartis, Ipsen Biopharma, Novartis, Pfizer, Bausch Health and Ono Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Neuroendocrine Tumors pipeline constitutes 70+ key companies continuously working towards developing 75+ Neuroendocrine Tumors treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Hypoglycemia Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Amphastar Pharma, Eiger BioPharma, Eli Lilly, Novo Nordisk, Xeris Pharma

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hypoglycemia pipeline constitutes 10+ key companies continuously working towards developing 12+ Hypoglycemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.   … Continue reading →

Hepatocellular Carcinoma Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Saronic Biotech, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Hepatocellular Carcinoma pipeline constitutes 90+ key companies continuously working towards developing 95+ Hepatocellular Carcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Insulin Resistance Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Exscien Corp, Glycomantra, Hanmi Pharma, NorthSea Therapeutics BV

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Insulin Resistance pipeline constitutes 8+ key companies continuously working towards developing 10+ Insulin Resistance treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes … Continue reading →

Motor Neuron Disease Treatment Pipeline Shows Strong Momentum as 180+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Motor Neuron Disease Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Motor Neuron Disease pipeline landscape. It covers the Motor Neuron Disease pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

Metastatic Hormone Refractory Prostate Cancer Clinical Trial Pipeline Expands as 180+ Companies Driving Innovation in the Therapeutics | DelveInsight

DelveInsight’s, “Metastatic Hormone Refractory Prostate Cancer Pipeline Insight 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Metastatic Hormone Refractory Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. … Continue reading →

Non-Hodgkin’s Lymphoma Clinical Trial Pipeline Shows Potential with Active Contributions from 180+ Key Companies | DelveInsight

DelveInsight’s, “Non-Hodgkin Lymphoma Pipeline Insights 2025” report provides comprehensive insights about 180+ companies and 200+ pipeline drugs in Non-Hodgkin Lymphoma pipeline landscape. It covers the Non-Hodgkin’s Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →